International Stem Cell Corporation to Present at the Southern California Investor Conference on Monday, August 29th

International Stem Cell Corporation to Present at the Southern California Investor Conference on Monday, August 29th

Already a Member? Log In to Your Account

International Stem Cell Corporation to Present at the Southern California Investor Conference on Monday, August 29th

 International Stem Cell Corporation to Present at the Southern California Investor Conference on Monday, August 29th

International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, will be presenting at the 2011 Southern California Investor Conference on Monday, August 29, 2011 at 1:30 p.m. Pacific (4:30 p.m. Eastern). The conference takes place at The Island Hotel in Newport Beach, California.

The Southern California Investor Conference is the only conference focused exclusively on the wealth of exciting growth companies from Southern California. The annual one-day conference features more than 35 companies from the region presenting to attendees from throughout the nation. The conference is open to the public and investors can find a list of 2011 presenting companies and registration information at www.CaliforniaStocks.com

A webcast of the International Stem Cell Corporation presentation will be accessible online athttp://events.powerstream.net/002/00271/20110829_SCIC_T2/ or from the link on the Company's web site at www.internationalstemcell.com. An archived version will be available for 30 days.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. 

  Article Info
Created: Aug 23 2011 at 11:54:18 AM
Updated: Aug 23 2011 at 11:54:18 AM
Category: Finance & Investment
Language: English

  Share
Stumbleupon
Digg
Delicious
Reddit
© 2006-2014 OnToplist.com, All Rights Reserved